|
| Press Releases |
|
 |
|
| Monday, July 2, 2018 |
|
|
Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder |
| The symposium will report on the latest data on lemborexant from non-clinical research and clinical studies relating to insomnia, including the results of SUNRISE 1. more info >> |
|
| Friday, June 22, 2018 |
|
|
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN) |
| Eisai Co., Ltd. announced today that it has been selected for the first time for membership in the MSCI Japan Empowering Women Index (WIN), an index developed for environmental, social and governance (ESG) investment. more info >> |
|
|
エーザイ、「MSCI日本株女性活躍指数（WIN）」の構成銘柄に選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび環境、社会、ガバナンス（ESG）投資のために開発された「MSCI 日本株女性活躍指数（WIN）」の構成銘柄に、初めて選定されましたのでお知らせします。本指数は、年金積立金管理運用独立行政法人（GPIF）が、非財務価値であるESGの取り組みに基づいた投資を行うために選定する指数の一つとして採用されています。 more info >> |
|
|
アッヴィとエーザイ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」の新たな小児用製剤「ヒュミラ(R)皮下注20mgシリンジ0.2mL」を発売 |
| アッヴィ合同会社とエーザイ株式会社は、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」（一般名：アダリムマブ＜遺伝子組換え＞、以下「ヒュミラ」）の新たな小児用製剤「ヒュミラ(R)皮下注20mgシリンジ0.2mL」について、6月15日に薬価基準に収載されたことを受け、本日、発売したことをお知らせします。 more info >> |
|
| Thursday, June 21, 2018 |
|
|
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL |
| AbbVie GK and Eisai Co., Ltd. announced that HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, a new pediatric formulation of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody formulation, has been launched today after being listed in the National Health Insurance reimbursement price list on June 15. more info >> |
|
| Thursday, June 14, 2018 |
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research |
| Eisai Co., Ltd. announced today that its research subsidiary KAN Research Institute, Inc. has entered into an industry-academia-government joint research agreement with six joint research organizations concerning the "nucleic drug discovery research using novel nucleic acid synthesis and delivery technologies" research project represented by KAN. more info >> |
|
| Wednesday, June 13, 2018 |
|
|
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA |
| Eisai Co., Ltd. has announced that it has decided to establish the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility focused on immuno-dementia based on human genetics, aimed at innovative drug discovery in the field of dementia, in Cambridge, Massachusetts, the United States. more info >> |
|
|
エーザイ、米国マサチューセッツ州ケンブリッジに新たな研究所Eisai Center for Genetics Guided Dementia Discoveryを設立 |
| エーザイ株式会社は、このたび米国マサチューセッツ州ケンブリッジに、認知症領域での革新的創薬を志向したヒト遺伝学（Human Genetics）に基づく認知症神経免疫療法（Immuno-Dementia）にフォーカスした新たな探索研究所（Eisai Center for Genetics Guided Dementia Discovery）を設立することを決定しましたのでお知らせします。 more info >> |
|
| Monday, June 11, 2018 |
|
|
アッヴィ・エーザイ・EAファーマ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」とオート・インジェクター製剤「ヒュミラ(R)皮下注ペン」を新発売 |
| アッヴィ合同会社とエーザイ株式会社およびその消化器事業子会社であるEAファーマ株式会社は、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」（一般名：アダリムマブ＜遺伝子組換え＞、以下「ヒュミラ」）のオート・インジェクター製剤「ヒュミラ(R)皮下注40mgペン0.4mL」、および「ヒュミラ(R)皮下注80mgペン0.8mL」について、5月30日に薬価基準に収載されたことを受け、本日、発売したことをお知らせいたします。 more info >> |
|
|
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA |
| The newly launched pen-type auto-injector devices were developed to simplify the operation and reduce the burden on patients when performing self-injection. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Maxon、リアルタイム建築ビジュアライゼーションソリューションでAEC市場に正式参入
Mar 17, 2026 23:05: JST
|
|
|
Maxon, 실시간 Archviz 솔루션으로 AEC 시장 공식 진출
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon推出即時Archviz解決方案，正式進軍AEC市場
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon推出实时Archviz解决方案，正式进军AEC市场
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon Marks Its Official Entry Into the AEC Market With Its Real-Time Archviz Solution
Mar 17, 2026 22:05 HKT/SGT
|
|
|
FinHarbor Introduces Rapid-Deployment Neobank Platform for 30-Day Go-Live
Mar 17, 2026 22:00: JST
|
|
|
FinHarbor Introduces Rapid-Deployment Neobank Platform for 30-Day Go-Live
Mar 17, 2026 22:00 HKT/SGT
|
|
|
Geo Energy's Integrated Infrastructure Project Achieves 80% Completion; Secures Two Binding Term Sheets with Third Parties for 9 Million Tonnes Annual Haulage; Coal Prices Surge Amid Global Tensions
Mar 17, 2026 22:00 HKT/SGT
|
|
|
FILMART and EntertainmentPulse open today
Mar 17, 2026 21:41: JST
|
|
|
FILMART and EntertainmentPulse open today
Mar 17, 2026 20:41 HKT/SGT
|
|
|
鍋圈(2517.HK)核心經營利潤勁增 四店齊發驅動長期成長
Mar 17, 2026 20:30 HKT/SGT
|
|
|
锅圈(2517.HK)核心经营利润劲增 四店齐发驱动长期成长
Mar 17, 2026 20:24 HKT/SGT
|
|
|
GUOQUAN FOOD (2517.HK) Surging core operating profit, Four Stores Jointly Advancing with Concerted Efforts for Long-Term Growth
Mar 17, 2026 20:15 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL GROUP Provides Medals, Commemorative Items, and Trophies as Category Sponsor (Awards Ceremonies) for the LIGA.i Blind Soccer Top League 2025
Mar 17, 2026 21:00 JST
|
|
|
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
Mar 17, 2026 19:49 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
